Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

European Union promotes research to prevent complication after transplantation of stem cells

27.02.2015

Two Berlin research teams led by Marie-Laure Yaspo at the Max Planck Institute for Molecular Genetics and Hans Lehrach at Alacris Theranostics GmbH in Berlin are partners in the TREGeneration consortium. Their goal is to develop new strategies for the treatment of Graft versus Host Disease, a serious complication following bone marrow transplantation. A total of 6 million euros was awarded to the consortium to perform a 5-year research project comprising a set of five parallel clinical trials.

Transplantation of stem cells can save the life of patients suffering from leukemia or other blood diseases. Between 30 and 50% of patients undergoing stem cell transplantation suffer from graft versus host disease, a potentially serious condition that results from donor immune cells "attacking" patient tissues like skin, internal organs and mucosa. The TREGeneration project aims to test a cell-based therapeutic approach, expected to result in fewer side effects than the pharmacological strategies currently available.

The project is centered on five clinical trials conducted in parallel by five groups in different European countries. In each trial, patients will be treated with a particular blood cell population called regulatory T cells purified from blood of the original bone marrow donor. These cells have the capacity to suppress the tissue damage caused by T cells from the transplanted bone marrow. These early clinical trials (phase I/II) aim to identify the safe dose to be administered and also to generate preliminary efficacy data.

The task of the Berlin groups of Marie-Laure Yaspo at the Max Planck Institute for Molecular Genetics and Hans Lehrach from Alacris Theranostics GmbH is to characterize the “deep immune status” of patients and donors with a new technology developed by the two groups themselves.

Using next generation sequencing, the scientists will analyze the T cell receptor repertoires in the donor and patient samples at several times after treatment in order to track the fate of individual T cell clones and populations during the clinical trials. The results are expected to contribute to a better understanding of the immune suppressive effects of the regulatory T cell treatment on the patients.

The TREGeneration consortium is led by João Lacerda’s team at the Instituto de Medicina Molecular in Lisbon, Portugal, and comprises eight partners from five European countries. The clinical trials will be run independently by each center and are led by proejct participants: João Forjaz de Lacerda at the Hospital de Santa Maria in Lisbon; Matthias Edinger at the Universitätsklinik in Regensburg, Germany; Frédéric Baron at the Laboratory of Cell and Gene Therapy, Sart-Tilman in Liège, Belgium; and Mario Arpinati at the Department of Hematology “Seràgnoli”, University Hospital S.Orsola-Malpighi, Bologna, Italy.

The data generated by the different clinical trials will be integrated within the framework of the statistical analysis performed by Marta García-Fiñana’s team from the Department of Biostatistics, Faculty of Health & Life Sciences, University of Liverpool, UK. GABO:mi from Munich, Germany, is the project management partner.

Background information

The European Research Program Horizon 2020

The European Union regularly announces research programs in order to develop and strenghten the European Research and Innovation Area by funding cross-border research projects. Horizon 2020 is the biggest EU Research and Innovation program ever with nearly €80 billion of funding available over 7 years (2014 to 2020). By fostering international collaboration in research and innovation, Horizon 2020 addresses the huge social challenges like fighting diseases, securing enery requirements or adapting to climate changes. It will support scientists all over the world to collaborate and find solutions for problems of social and global interest.

Weitere Informationen:

http://www.molgen.mpg.de

Dr. Patricia Marquardt | Max-Planck-Institut für molekulare Genetik

More articles from Awards Funding:

nachricht CRTD receives 1.56 Mill. Euro BMBF-funding for retinal disease research
24.05.2017 | DFG-Forschungszentrum für Regenerative Therapien TU Dresden

nachricht BMBF funds translational project to improve radiotherapy
10.05.2017 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

All articles from Awards Funding >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can the immune system be boosted against Staphylococcus aureus by delivery of messenger RNA?

Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.

Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

Im Focus: World's thinnest hologram paves path to new 3-D world

Nano-hologram paves way for integration of 3-D holography into everyday electronics

An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

How herpesviruses win the footrace against the immune system

26.05.2017 | Life Sciences

Water forms 'spine of hydration' around DNA, group finds

26.05.2017 | Life Sciences

First Juno science results supported by University of Leicester's Jupiter 'forecast'

26.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>